

Yingjie Ji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5923879/publications.pdf>

Version: 2024-02-01

23
papers

1,623
citations

516710

16
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

1216
citing authors

#	ARTICLE	IF	CITATIONS
1	E-Test or Agar Dilution for Metronidazole Susceptibility Testing of <i>Helicobacter pylori</i> : Importance of the Prevalence of Metronidazole Resistance. <i>Frontiers in Microbiology</i> , 2022, 13, 801537.	3.5	2
2	Chinese Consensus Report on Family-Based <i>Helicobacter pylori</i> Infection Control and Management (2021 Edition). <i>Gut</i> , 2022, 71, 238-253.	12.1	81
3	Susceptibility testing alone will not reliably achieve high <i>Helicobacter pylori</i> cure rates: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	2.8	1
4	Primary Antibiotic Resistance of <i>Helicobacter pylori</i> in Different Regions of China: A Systematic Review and Meta-Analysis. <i>Pathogens</i> , 2022, 11, 786.	2.8	24
5	<i>Helicobacter pylori</i> diagnosis and therapy in the era of antimicrobial stewardship. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110640.	3.2	28
6	Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112.	12.1	239
7	Susceptibility-guided therapy for <i>Helicobacter pylori</i> infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. <i>Helicobacter</i> , 2020, 25, e12699.	3.5	14
8	Analysis of by high-throughput sequencing: <i>Helicobacter pylori</i> infection and salivary microbiome. <i>BMC Oral Health</i> , 2020, 20, 84.	2.3	24
9	14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line <i>Helicobacter pylori</i> Treatment. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3639-3646.	2.3	16
10	Editorial: not yet time for universal susceptibility-guided first-line <i>Helicobacter pylori</i> treatment—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 332-332.	3.7	0
11	Susceptibility-guided therapy for <i>Helicobacter pylori</i> infection treatment failures. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987492.	3.2	27
12	High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line <i>Helicobacter pylori</i> therapy: A randomized trial. <i>Helicobacter</i> , 2019, 24, e12596.	3.5	52
13	Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line <i>Helicobacter pylori</i> treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1385-1394.	3.7	79
14	Relative potency of proton-pump inhibitors, <i>Helicobacter pylori</i> therapy cure rates, and meaning of double-dose PPI. <i>Helicobacter</i> , 2019, 24, e12554.	3.5	61
15	Fifth Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2018, 23, e12475.	3.5	304
16	Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple <i>Helicobacter pylori</i> therapy despite a high prevalence of antimicrobial resistance. <i>Helicobacter</i> , 2018, 23, e12485.	3.5	39
17	RNAS22 impairs the sperm motility via PKA/PI3K/calcium signal pathways. <i>Reproduction</i> , 2018, 155, 383-392.	2.6	19
18	Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for <i>Helicobacter pylori</i> eradication treatment. <i>PLoS ONE</i> , 2018, 13, e0189888.	2.5	23

#	ARTICLE	IF	CITATIONS
19	Treating <i>Helicobacter pylori</i> effectively while minimizing misuse of antibiotics. Cleveland Clinic Journal of Medicine, 2017, 84, 310-318.	1.3	53
20	Rescue Therapy for <i>Helicobacter pylori</i> Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. American Journal of Gastroenterology, 2016, 111, 1736-1742.	0.4	70
21	Role of bismuth in improving <i>Helicobacter pylori</i> eradication with triple therapy. Gut, 2016, 65, 870-878.	12.1	197
22	Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line <i>Helicobacter pylori</i> therapy. Gut, 2015, 64, 1715-1720.	12.1	129
23	Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant <i>Helicobacter pylori</i> Infections in a Prospective Study. Clinical Gastroenterology and Hepatology, 2013, 11, 802-807.e1.	4.4	140